Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiangyi Meng

Showing results (111-120 of 135) with videos related to

Pageof 14
Sort By:
Journal of the American College of Cardiology|August 29, 2020
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System AntagonistsAndrew P Ambrosy, Eugene Braunwald, David A Morrow, et al.
Brain Injury|February 5, 2009
Long-term effects of rivastigmine capsules in patients with traumatic brain injuryJonathan M Silver, Barbara Koumaras, Xiangyi Meng, et al.
Neurosurgical Review|September 18, 2024
Prediction model for poor short-term prognosis in patients with chronic subdural hematoma after burr hole drainage: a retrospective cohort studyJie Zhang, Aili Gao, Xiangyi Meng, et al.
World Neurosurgery|November 25, 2023
Risk Factors for Seizures After Titanium Cranioplasty: Five-Year Experience from a Single InstitutionXiangyi Meng, Hao Liu, Jie Zhang, et al.
Advances in Therapy|June 8, 2017
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 TrialsSandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, et al.
Multiple Sclerosis and Related Disorders|July 28, 2020
Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes<sup>✰</sup>Samuel F Hunter, Florian P Thomas, Mark Cascione, et al.
Advances in Therapy|April 12, 2017
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 TrialsSandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 13, 2019
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MSEdward J Fox, Fred D Lublin, Jerry S Wolinsky, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 5, 2017
Unraveling the Solution-State Supramolecular Structures of Donor-Acceptor Polymers and their Influence on Solid-State Morphology and Charge-Transport PropertiesYu-Qing Zheng, Ze-Fan Yao, Ting Lei, et al.
Rheumatology and Therapy|July 4, 2021
Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 StudiesAna-Maria Orbai, M Elaine Husni, Dafna D Gladman, et al.
Pageof 14

Showing results (111-120 of 135) with videos related to

Sort By:
Pageof 14
Journal of the American College of Cardiology|August 29, 2020
Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System AntagonistsAndrew P Ambrosy, Eugene Braunwald, David A Morrow, et al.
Brain Injury|February 5, 2009
Long-term effects of rivastigmine capsules in patients with traumatic brain injuryJonathan M Silver, Barbara Koumaras, Xiangyi Meng, et al.
Neurosurgical Review|September 18, 2024
Prediction model for poor short-term prognosis in patients with chronic subdural hematoma after burr hole drainage: a retrospective cohort studyJie Zhang, Aili Gao, Xiangyi Meng, et al.
World Neurosurgery|November 25, 2023
Risk Factors for Seizures After Titanium Cranioplasty: Five-Year Experience from a Single InstitutionXiangyi Meng, Hao Liu, Jie Zhang, et al.
Advances in Therapy|June 8, 2017
Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 TrialsSandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, et al.
Multiple Sclerosis and Related Disorders|July 28, 2020
Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes<sup>✰</sup>Samuel F Hunter, Florian P Thomas, Mark Cascione, et al.
Advances in Therapy|April 12, 2017
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 TrialsSandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 13, 2019
Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MSEdward J Fox, Fred D Lublin, Jerry S Wolinsky, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 5, 2017
Unraveling the Solution-State Supramolecular Structures of Donor-Acceptor Polymers and their Influence on Solid-State Morphology and Charge-Transport PropertiesYu-Qing Zheng, Ze-Fan Yao, Ting Lei, et al.
Rheumatology and Therapy|July 4, 2021
Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 StudiesAna-Maria Orbai, M Elaine Husni, Dafna D Gladman, et al.
Pageof 14